Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Equillium Inc (NQ: EQ ) 0.7851 -0.0248 (-3.06%) Streaming Delayed Price Updated: 3:58 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Equillium Inc < Previous 1 2 3 Next > Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates May 11, 2023 From Equillium, Inc. Via Business Wire Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation April 24, 2023 From Equillium, Inc. Via Business Wire Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates March 23, 2023 From Equillium, Inc. Via Business Wire Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference March 22, 2023 From Equillium, Inc. Via Business Wire Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR February 17, 2023 From Equillium, Inc. Via Business Wire Equillium to Present at the SVB Securities Annual Global Healthcare Conference February 07, 2023 From Equillium, Inc. Via Business Wire Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR January 13, 2023 From Equillium, Inc. Via Business Wire Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement December 23, 2022 From Equillium, Inc. Via Business Wire Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis December 16, 2022 From Equillium, Inc. Via Business Wire Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab December 06, 2022 From Equillium, Inc. Via Business Wire Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates November 14, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022 November 14, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata November 10, 2022 From Equillium, Inc. Via Business Wire Equillium to Present at Two Upcoming Investor Conferences November 08, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit November 03, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease November 02, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference October 26, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis September 27, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022 September 15, 2022 From Equillium, Inc. Via Business Wire EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to Shareholders September 06, 2022 From Halper Sadeh LLP Via Business Wire Equillium to Acquire Metacrine in All-Stock Transaction September 06, 2022 From Equillium, Inc. Via Business Wire Equillium to Present at Two Upcoming Investor Conferences August 31, 2022 From Equillium, Inc. Via Business Wire Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates August 15, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit July 28, 2022 From Equillium, Inc. Via Business Wire Equillium to Present at Two Upcoming Investor Conferences May 17, 2022 From Equillium, Inc. Via Business Wire Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates May 12, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association May 12, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists May 09, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR April 25, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology April 04, 2022 From Equillium, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.